Oculis (NASDAQ:OCS) Shares Gap Up – Here’s Why

Oculis Holding AG (NASDAQ:OCS)’s stock price gapped up prior to trading on Thursday . The stock had previously closed at $16.99, but opened at $17.40. Oculis shares last traded at $17.40, with a volume of 1,091 shares changing hands.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reissued a “buy” rating and set a $30.00 price target on shares of Oculis in a research report on Monday, November 11th. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has an average rating of “Buy” and an average target price of $29.20.

Oculis Trading Down 0.6 %

The company has a debt-to-equity ratio of 0.01, a quick ratio of 4.02 and a current ratio of 4.02. The business’s 50-day moving average price is $16.16 and its 200 day moving average price is $13.51. The company has a market cap of $686.95 million, a P/E ratio of -8.79 and a beta of -0.34.

Oculis Company Profile

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.